ASTELLAS PHARMA

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 2005-01-01

Employees: -

Market Cap: $22.5B

Website: https://www.astellas.com/

Clinical Trials

A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: ipragliflozin

First Posted Date: 2012-08-27

Last Posted Date: 2024-11-08

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 174

Registration Number: NCT01672762

A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Placebo
Drug: peficitinib

First Posted Date: 2012-07-25

Last Posted Date: 2024-10-21

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 281

Registration Number: NCT01649999

A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015K

Phase 3

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Peficitinib

First Posted Date: 2012-07-11

Last Posted Date: 2024-10-28

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 843

Registration Number: NCT01638013

Locations: 🇯🇵
JP00131, Fukuoka, Japan
🇯🇵
JP00164, Fukuoka, Japan
🇯🇵
JP00176, Fukui, Japan

and more 172 locations

A Study to Assess the Safety and Pharmacokinetics of Isavuconazole in Healthy Chinese Volunteers

Phase 1

Completed

Conditions: Pharmacokinetics of BAL4815
Pharmacokinetics of BAL8728
Healthy Volunteers

Interventions: Drug: Isavuconazole
Drug: Isavuconazole (IV)

First Posted Date: 2012-03-16

Last Posted Date: 2013-02-01

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 36

Registration Number: NCT01555918

Locations: 🇨🇳
Huashan Hospital, Shanghai, China

A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Placebo
Drug: peficitinib
Drug: methotrexate

First Posted Date: 2012-03-15

Last Posted Date: 2024-10-21

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 379

Registration Number: NCT01554696

Locations: 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸
The Center for Rheumatology and Bone Research, Wheaton, Maryland, United States
🇧🇪
Hospital Erasme, Brussels, Belgium

and more 46 locations

Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder

Phase 1

Completed

Conditions: Neurogenic Detrusor Overactivity
Overactive Bladder

Interventions: Drug: Solifenacin succinate suspension 5 mg

First Posted Date: 2012-02-27

Last Posted Date: 2024-10-22

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 14

Registration Number: NCT01539707

Locations: 🇧🇪
Site: 3201, Gent, Belgium
🇹🇷
Site: 90, Ankara, Turkey
🇬🇧
Site: 44, Sheffield, United Kingdom

and more 3 locations

Drug Interaction Study of Isavuconazole and Tacrolimus

Phase 1

Completed

Conditions: Pharmacokinetics of Isavuconazole
Pharmacokinetics of Tacrolimus
Healthy Volunteers

Interventions: Drug: isavuconazole
Drug: tacrolimus

First Posted Date: 2012-02-17

Last Posted Date: 2012-02-17

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 24

Registration Number: NCT01535547

Locations: 🇺🇸
Covance, Madison, Wisconsin, United States

A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

Phase 2

Completed

Conditions: Castration-Resistant Prostate Cancer (CRPC)

Interventions: Drug: Enzalutamide

First Posted Date: 2012-02-16

Last Posted Date: 2024-12-06

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 52

Registration Number: NCT01534052

Locations: 🇲🇩
Site MD37301, Chisinau, Moldova, Republic of
🇿🇦
Site ZA2701, George, South Africa
🇿🇦
Site ZA2702, Port Elizabeth, South Africa

and more 4 locations

A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)

Phase 3

Completed

Conditions: Diabetic Peripheral Neuropathy
Pain

Interventions: Drug: Placebo
Drug: Capsaicin 8%

First Posted Date: 2012-02-15

Last Posted Date: 2015-11-04

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 369

Registration Number: NCT01533428

Locations: 🇺🇸
Site: 130, Walnut Creek, California, United States
🇺🇸
Site: 125, Anniston, Alabama, United States
🇺🇸
Site: 116, Los Angeles, California, United States

and more 26 locations

A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly Subjects

Phase 1

Completed

Conditions: Pharmacokinetic of YM150
Healthy Elderly Subject

Interventions: Drug: YM150
Drug: Placebo

First Posted Date: 2012-01-23

Last Posted Date: 2012-01-24

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 36

Registration Number: NCT01514825

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy